{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:09:33Z","timestamp":1753891773001,"version":"3.41.2"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Neurofibromatosis type 1 (NF type 1) is an autosomal dominant disease with typical clinical manifestations, such as skin lesions, Lisch nodules, optic pathway gliomas, and neurofibromas, caused by the mutation of the NF1 gene. Visual evoked potentials (VEP) present a measure of the electrophysiological response of visual cortex to a visual stimulus. The role of VEP in the pathophysiology of NF type 1 is very complex and requires additional research.<\/jats:p><\/jats:sec><jats:sec><jats:title>The Aim<\/jats:title><jats:p>We examined the differences between NF type 1 patients with normal and altered VEP and analyzed the correlation between the prolongation of P100 latency and disease severity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>Two groups were formed: a control group and a study group with NF type 1 patients. Based on the control group analysis, a threshold value for a normal VEP finding of 116\u2009ms was obtained, and it was used to divide the study group into subgroups with normal and altered VEP. We proceeded with examining the differences in clinical manifestations of the disease between the subgroups, after which we checked if there is a correlation between the prolongation of the P100 latency and the severity of the clinical picture according to the Riccardi scale. Statistical analysis was performed using the Pearson chi-square test and the Spearman correlation test in the program SPSS 28.0, with levels of statistical significance <jats:italic>p<\/jats:italic>\u2009=\u20090.05 and <jats:italic>p<\/jats:italic>\u2009=\u20090.001.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the group with the abnormal VEP we found a statistically significant more frequent occurrence of optic tract glioma (<jats:italic>p<\/jats:italic>\u2009=\u20090.008), tumors (<jats:italic>p<\/jats:italic>\u2009=\u20090.032), epilepsy (<jats:italic>p<\/jats:italic>\u2009=\u20090.043), and cognitive disorders (<jats:italic>p<\/jats:italic>\u2009=\u20090.028), while the other clinical signs had an equal prevalence in both groups. A moderately strong correlation (<jats:italic>r<\/jats:italic><jats:sub>s<\/jats:sub>\u2009=\u20090.665) was observed between the prolongation of P100 latency and the severity of the clinical picture.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our results showed the important role of VEP in the description of clinical phenotypes of NF type 1. The authors of the study propose VEP to be included in the diagnostic algorithms designed for patients with NF type 1.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2024.1410101","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T04:46:13Z","timestamp":1721623573000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of visual evoked potentials in patients with neurofibromatosis type 1: new concepts"],"prefix":"10.3389","volume":"15","author":[{"given":"Jasna","family":"Jancic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikola","family":"Zarkovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blazo","family":"Nikolic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikola","family":"Ivancevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Branislav","family":"Rovcanin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dejan","family":"Nesic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-3-319-92450-2_2","article-title":"Genetics and pathway in Neurofibromatosis type 1","volume-title":"Multidisciplinary approach to Neurofibromatosis type 1","author":"Denayer","year":"2020"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e22376","DOI":"10.7759\/cureus.22376","article-title":"A Clinico-epidemiological study of Neurofibromatosis type 1 and its relation to quality of life: a cross-sectional study from India","volume":"14","author":"Mahajan","year":"2022","journal-title":"Cureus"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00439-021-02410-z","article-title":"Challenges in the diagnosis of neurofibromatosis type 1 (NF1) in young children facilitated by means of revised diagnostic criteria including genetic testing for pathogenic NF1 gene variants","volume":"141","author":"Kehrer-Sawatzki","year":"2022","journal-title":"Hum Genet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e2077","DOI":"10.1002\/mgg3.2077","article-title":"Characterization of health concerns in people with neurofibromatosis type 1","volume":"11","author":"Fleming","year":"2023","journal-title":"Mol Genet Genomic Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"842","DOI":"10.7326\/0003-4819-144-11-200606060-00010","article-title":"Pathophysiology of Neurofibromatosis type 1","volume":"144","author":"Theos","year":"2006","journal-title":"Ann Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s12887-021-02791-0","article-title":"Diagnostic difficulties and possibilities of NF1-like syndromes in childhood","volume":"21","author":"Pinti","year":"2021","journal-title":"BMC Pediatr"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1146\/annurev-neuro-060909-153215","article-title":"Molecular and cellular mechanisms of learning disabilities: AFocus on NF1","volume":"33","author":"Shilyansky","year":"2010","journal-title":"Annu Rev Neurosci"},{"key":"ref8","first-page":"96","article-title":"Visual evoked potentials","volume-title":"Clinical evoked potentials","author":"Omkar","year":"2020"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.14253\/acn.2018.20.1.12","article-title":"Basic requirements for visual evoked potentials","volume":"20","author":"Seok","year":"2018","journal-title":"Ann Clin Neurophysiol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"ii16","DOI":"10.1136\/jnnp.2005.068130","article-title":"The clinical role of evoked potentials","volume":"76","author":"Walsh","year":"2005","journal-title":"Neurol Neurosurg Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/B978-0-444-64032-1.00034-5","article-title":"Visually evoked potentials","volume":"160","author":"Creel","year":"2019","journal-title":"Handb Clin Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.4103\/ijo.IJO_2480_20","article-title":"Normative values of visual evoked potential in adults","volume":"69","author":"Ekayanti","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/med\/9780195385113.003.0022","article-title":"Visual evoked potentials","volume-title":"Clinical neurophysiology","author":"Carter","year":"2009"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10633-013-9399-5","article-title":"Role of visual evoked potentials in the assessment and management of optic pathway gliomas in children","volume":"127","author":"Mierlo","year":"2013","journal-title":"Doc Ophthalmol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1001\/archneur.1985.04060100054022","article-title":"The value of visual evoked potential as a screening test in neurofibromatosis","volume":"42","author":"Jabbari","year":"1985","journal-title":"Arch Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/00004691-199207010-00004","article-title":"Visual evoked potentials in infants and children","volume":"9","author":"Taylor","year":"1992","journal-title":"J Clin Neurophysiol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/0887-8994(94)90043-4","article-title":"Optic gliomas in neurofibromatosis type 1: role of visual evoked potentials","volume":"10","author":"North","year":"1994","journal-title":"Pediatr Neurol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/00004703-199608000-00004","article-title":"Children and adolescents with neurofibromatosis 1: a behavioral phenotype","volume":"17","author":"Dilts","year":"1996","journal-title":"Dev Behav Pediatr"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.clinph.2022.08.009","article-title":"Plasticity of visual evoked potentials in patients with neurofibromatosis type 1","volume":"142","author":"Castricum","year":"2022","journal-title":"Clin Neurophysiol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/s41436-021-01170-5","article-title":"Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation","volume":"23","author":"Legius","year":"2021","journal-title":"Genet Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10633-016-9553-y","article-title":"ISCEV standard for clinical visual evoked potentials: (2016 update)","volume":"133","author":"Odom","year":"2016","journal-title":"Doc Ophthalmol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/00004691-200604000-00011","article-title":"Guideline 9B: Guidelines on visual evoked potentials","volume":"23","year":"2006","journal-title":"J Clin Neurophysiol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1001\/archderm.137.11.1421","article-title":"Quality-of-life impairment in neurofibromatosis type 1: a cross-sectional study of 128 cases","volume":"137","author":"Wolkenstein","year":"2001","journal-title":"Arch Dermatol"},{"key":"ref24","first-page":"160","article-title":"An epidemiological, clinical and genetic survey of Neurofibromatosis type 1 in children under sixteen years of age","volume":"77","author":"McKeever","year":"2008","journal-title":"Ulster Med J"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1055\/s-0034-1382021","article-title":"Neurofibromatosis type 1 (NF1) and associated tumors","volume":"226","author":"Rosenbaum","year":"2014","journal-title":"Klin Padiatr"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/B978-0-444-64076-5.00051-X","article-title":"Neurofibromatosis type 1","volume":"148","author":"Anderson","year":"2015","journal-title":"Handb Clin Neurol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/(SICI)1096-8628(19970516)70:2<138::AID-AJMG7>3.0.CO;2-U","article-title":"Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients","volume":"70","author":"Friedman","year":"1997","journal-title":"Am J Med Genet"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1177\/088307380201700802","article-title":"Neurofibromatosis 1: clinical manifestations and diagnostic criteria","volume":"17","author":"Friedman","year":"2002","journal-title":"J Child Neurol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/978-1-59745-271-7_25","article-title":"Visual evoked potentials","volume-title":"The clinical neurophysiology primer","author":"Drislane","year":"2007"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e20190660","DOI":"10.1542\/peds.2019-0660","article-title":"Health supervision for children with Neurofibromatosis type 1","volume":"143","author":"Miller","year":"2019","journal-title":"Pediatrics"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jaapos.2006.02.004","article-title":"Can screening for optic nerve gliomas in patients with neurofibromatosis type I be performed with visual-evoked potential testing?","volume":"10","author":"Wolsey","year":"2006","journal-title":"J AAPOS"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1177\/1120672120906989","article-title":"Role of visual evoked potentials and optical coherence tomography in the screening for optic pathway gliomas in patients with neurofibromatosis type I","volume":"31","author":"Vagge","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41433-022-02096-1","article-title":"Visual outcomes and predictors in optic pathway glioma: a single Centre study","volume":"37","author":"Bowman","year":"2023","journal-title":"Eye"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10633-023-09920-3","article-title":"The role of visual electrodiagnostics in management of children with neurofibromatosis type 1","volume":"146","author":"Tekav\u010di\u010d Pompe","year":"2023","journal-title":"Doc Ophthalmol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.1212\/WNL.96.15_supplement.5007","article-title":"Visual evoked potentials findings in children diagnosed with neurofibromatosis type 1","volume":"96","author":"Carrion","year":"2021","journal-title":"Neurology"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.visres.2020.05.003","article-title":"Developments in non-invasive visual electrophysiology","volume":"174","author":"Kremers","year":"2020","journal-title":"Vis Res"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/B978-0-12-804281-6.00011-2","article-title":"Executive functions","volume":"163","author":"Cristofori","year":"2019","journal-title":"Handb Clin Neurol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/ng0397-281","article-title":"A mouse model for the learning and memory deficits associated with neurofibromatosis type I","volume":"15","author":"Silva","year":"1997","journal-title":"Nat Genet"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/nature711","article-title":"Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1","volume":"415","author":"Costa","year":"2002","journal-title":"Nature"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1177\/088307380201700813","article-title":"Molecular and cellular mechanisms underlying the cognitive deficits associated with neurofibromatosis 1","volume":"17","author":"Costa","year":"2002","journal-title":"J Child Neurol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1111\/j.1460-9568.2005.04007.x","article-title":"Long-term potentiation of human visual evoked responses","volume":"21","author":"Teyler","year":"2005","journal-title":"Eur J Neurosci"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform Neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N Engl J Med"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of Selumetinib in Neurofibromatosis type 1-related plexiform Neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1410101\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T04:46:16Z","timestamp":1721623576000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1410101\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":43,"alternative-id":["10.3389\/fneur.2024.1410101"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1410101","relation":{},"ISSN":["1664-2295"],"issn-type":[{"type":"electronic","value":"1664-2295"}],"subject":[],"published":{"date-parts":[[2024,7,22]]},"article-number":"1410101"}}